BRTX Receives Historic License to Revolutionize New York State Health Regimen

BioRestorative is excited to explore the potential of Mesenchymal Stem Cells (MSCs) as a source of treatments for many diseases, including diabetes. MSCs are incredibly versatile and adaptive adult stem cells, able to be manipulated in the laboratory to become cartilage, bone and fat cells. These specialized cells provide the body with numerous structural and functional benefits that keep us healthy.

They act like building blocks, ready and waiting to be transformed into the cells the body needs most. With their immense potential, MSCs could be the breakthrough we have been waiting for.

BRTX is thrilled to announce a new milestone: a license to act as a tissue bank. With this license, the company can optimize its ISO 7 certified clean room and manufacturing facility, and explore the ability to do contract manufacturing on behalf of other regenerative medicine companies.

But the most exciting capability of this license is the ability to bank BRTX-100 on behalf of future patients, and potentially provide those patients with an “off the shelf” autologous cell therapy product once FDA approved. This could provide a unique revenue opportunity to help offset some cash burn related to their laboratory.

BioRestorative is obtaining its license in 2021, which is positioning them as one of the leaders in the mesenchymal stem cell market. This market, which was worth a whopping $2.7 billion in 2022, is expected to witness an incredible 12.8% compound annual growth rate till 2030 – effectively doubling in size in this timeframe!

BioRestorative is leading the charge in developing novel treatments for a variety of diseases with their two major products. Their promising autologous stem cell product, BRTX-100, harvests, cultures, and injects stem cells from the patient’s own body.

ThermoStem®, on the other hand, is showing incredible results in the treatment of obesity and related diseases. With the help of their license, BioRestorative hopes to further accelerate the current BRTX-100 clinical trial, which is now in phase 2.

BioRestorative’s state-of-the-art facility has opened the door for major advancements in regenerative therapeutics, establishing the company as a leader in the space. This makes BioRestorative one to watch in the future, as not only can it further its own journey, but it can also help to facilitate the growth of other regenerative companies, too.

Leave a Comment